Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

The architecture of the IgG anti-carbohydrate repertoire in primary antibody deficiencies (PADs).

Jandus P, Frias Boligan K, Smith DF, de Graauw E, Grimbacher B, Jandus C, Abdelhafez MM, Despont A, Bovin N, Simon D, Rieben R, Simon HU, Cummings RD, von Gunten S.

Blood. 2019 Sep 19. pii: blood.2019001705. doi: 10.1182/blood.2019001705. [Epub ahead of print]

PMID:
31537530
2.

Immunophenotyping of Human Innate Lymphoid Cells.

Trabanelli S, Gomez-Cadena A, Jandus C.

Methods Mol Biol. 2019;2032:179-192. doi: 10.1007/978-1-4939-9650-6_10.

PMID:
31522419
3.

To be a tumor promoting or tumor suppressing ILC: That is the question.

Jandus C.

Semin Immunol. 2019 Feb;41:101283. doi: 10.1016/j.smim.2019.101283. Epub 2019 Jul 20. No abstract available.

PMID:
31337579
4.

The pro- and anti-tumor role of ILC2s.

Trabanelli S, Chevalier MF, Derré L, Jandus C.

Semin Immunol. 2019 Feb;41:101276. doi: 10.1016/j.smim.2019.04.004. Epub 2019 May 23. Review.

PMID:
31130471
5.

MicroRNA-155 Expression Is Enhanced by T-cell Receptor Stimulation Strength and Correlates with Improved Tumor Control in Melanoma.

Martinez-Usatorre A, Sempere LF, Carmona SJ, Carretero-Iglesia L, Monnot G, Speiser DE, Rufer N, Donda A, Zehn D, Jandus C, Romero P.

Cancer Immunol Res. 2019 Jun;7(6):1013-1024. doi: 10.1158/2326-6066.CIR-18-0504. Epub 2019 May 1.

PMID:
31043416
6.

High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells.

Costa-Nunes C, Cachot A, Bobisse S, Arnaud M, Genolet R, Baumgaertner P, Speiser DE, Sousa Alves PM, Sandoval F, Adotévi O, Reith W, Protti MP, Coukos G, Harari A, Romero P, Jandus C.

Clin Cancer Res. 2019 Jul 15;25(14):4320-4331. doi: 10.1158/1078-0432.CCR-18-1356. Epub 2019 Apr 23.

PMID:
31015344
7.

Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment.

Haas Q, Boligan KF, Jandus C, Schneider C, Simillion C, Stanczak MA, Haubitz M, Seyed Jafari SM, Zippelius A, Baerlocher GM, Läubli H, Hunger RE, Romero P, Simon HU, von Gunten S.

Cancer Immunol Res. 2019 May;7(5):707-718. doi: 10.1158/2326-6066.CIR-18-0505. Epub 2019 Apr 15.

PMID:
30988027
8.

Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab.

Kowalczyk-Quintas C, Chevalley D, Willen L, Jandus C, Vigolo M, Schneider P.

Front Immunol. 2018 Nov 20;9:2698. doi: 10.3389/fimmu.2018.02698. eCollection 2018.

9.

Lymphocyte-Derived Exosomal MicroRNAs Promote Pancreatic β Cell Death and May Contribute to Type 1 Diabetes Development.

Guay C, Kruit JK, Rome S, Menoud V, Mulder NL, Jurdzinski A, Mancarella F, Sebastiani G, Donda A, Gonzalez BJ, Jandus C, Bouzakri K, Pinget M, Boitard C, Romero P, Dotta F, Regazzi R.

Cell Metab. 2019 Feb 5;29(2):348-361.e6. doi: 10.1016/j.cmet.2018.09.011. Epub 2018 Oct 11.

PMID:
30318337
10.

Induction of Paracrine Signaling in Metastatic Melanoma Cells by PPARγ Agonist Rosiglitazone Activates Stromal Cells and Enhances Tumor Growth.

Pich C, Meylan P, Mastelic-Gavillet B, Nguyen TN, Loyon R, Trang BK, Moser H, Moret C, Goepfert C, Hafner J, Levesque MP, Romero P, Jandus C, Michalik L.

Cancer Res. 2018 Nov 15;78(22):6447-6461. doi: 10.1158/0008-5472.CAN-18-0912. Epub 2018 Sep 5.

PMID:
30185551
11.

Autocrine Adenosine Regulates Tumor Polyfunctional CD73+CD4+ Effector T Cells Devoid of Immune Checkpoints.

Gourdin N, Bossennec M, Rodriguez C, Vigano S, Machon C, Jandus C, Bauché D, Faget J, Durand I, Chopin N, Tredan O, Marie JC, Dubois B, Guitton J, Romero P, Caux C, Ménétrier-Caux C.

Cancer Res. 2018 Jul 1;78(13):3604-3618. doi: 10.1158/0008-5472.CAN-17-2405. Epub 2018 Mar 20.

12.

Innate lymphoid cells in antitumor immunity.

Salomé B, Jandus C.

J Leukoc Biol. 2018 Mar;103(3):479-483. doi: 10.1189/JLB.5MR0617-266R. Epub 2017 Dec 28. Review.

PMID:
29345362
13.

ATP Release from Chemotherapy-Treated Dying Leukemia Cells Elicits an Immune Suppressive Effect by Increasing Regulatory T Cells and Tolerogenic Dendritic Cells.

Lecciso M, Ocadlikova D, Sangaletti S, Trabanelli S, De Marchi E, Orioli E, Pegoraro A, Portararo P, Jandus C, Bontadini A, Redavid A, Salvestrini V, Romero P, Colombo MP, Di Virgilio F, Cavo M, Adinolfi E, Curti A.

Front Immunol. 2017 Dec 22;8:1918. doi: 10.3389/fimmu.2017.01918. eCollection 2017.

14.

Human innate lymphoid cells (ILCs): Toward a uniform immune-phenotyping.

Trabanelli S, Gomez-Cadena A, Salomé B, Michaud K, Mavilio D, Landis BN, Jandus P, Jandus C.

Cytometry B Clin Cytom. 2018 May;94(3):392-399. doi: 10.1002/cyto.b.21614. Epub 2018 Jan 31. Review.

15.

Dysregulated Innate Lymphocytes in Patients With Primary Antibody Deficiency Treated With Intravenous Immunoglobulin.

Vigano S, Trabanelli S, Indulsi F, Salomé B, Harari A, Romero P, Helbling A, Jandus C, Jandus P.

J Investig Allergol Clin Immunol. 2017;27(6):394-396. doi: 10.18176/jiaci.0200. No abstract available.

16.

Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis.

Romano M, Sollazzo D, Trabanelli S, Barone M, Polverelli N, Perricone M, Forte D, Luatti S, Cavo M, Vianelli N, Jandus C, Palandri F, Catani L.

Oncoimmunology. 2017 Jul 5;6(10):e1345402. doi: 10.1080/2162402X.2017.1345402. eCollection 2017.

17.

Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.

Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salomé B, Lecciso M, Salvestrini V, Verdeil G, Racle J, Papayannidis C, Morita H, Pizzitola I, Grandclément C, Bohner P, Bruni E, Girotra M, Pallavi R, Falvo P, Leibundgut EO, Baerlocher GM, Carlo-Stella C, Taurino D, Santoro A, Spinelli O, Rambaldi A, Giarin E, Basso G, Tresoldi C, Ciceri F, Gfeller D, Akdis CA, Mazzarella L, Minucci S, Pelicci PG, Marcenaro E, McKenzie ANJ, Vanhecke D, Coukos G, Mavilio D, Curti A, Derré L, Jandus C.

Nat Commun. 2017 Sep 19;8(1):593. doi: 10.1038/s41467-017-00678-2.

18.

ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence.

Chevalier MF, Trabanelli S, Racle J, Salomé B, Cesson V, Gharbi D, Bohner P, Domingos-Pereira S, Dartiguenave F, Fritschi AS, Speiser DE, Rentsch CA, Gfeller D, Jichlinski P, Nardelli-Haefliger D, Jandus C, Derré L.

J Clin Invest. 2017 Aug 1;127(8):2916-2929. doi: 10.1172/JCI89717. Epub 2017 Jun 26.

19.

Identification of innate lymphoid cells in single-cell RNA-Seq data.

Suffiotti M, Carmona SJ, Jandus C, Gfeller D.

Immunogenetics. 2017 Jul;69(7):439-450. doi: 10.1007/s00251-017-1002-x. Epub 2017 May 22.

PMID:
28534222
20.

Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope.

Baumgaertner P, Costa Nunes C, Cachot A, Maby-El Hajjami H, Cagnon L, Braun M, Derré L, Rivals JP, Rimoldi D, Gnjatic S, Abed Maillard S, Marcos Mondéjar P, Protti MP, Romano E, Michielin O, Romero P, Speiser DE, Jandus C.

Oncoimmunology. 2016 Sep 9;5(10):e1216290. eCollection 2016.

21.

The Vast Universe of T Cell Diversity: Subsets of Memory Cells and Their Differentiation.

Jandus C, Usatorre AM, Viganò S, Zhang L, Romero P.

Methods Mol Biol. 2017;1514:1-17. Review.

PMID:
27787788
22.

Modulation of mTOR Signalling Triggers the Formation of Stem Cell-like Memory T Cells.

Scholz G, Jandus C, Zhang L, Grandclément C, Lopez-Mejia IC, Soneson C, Delorenzi M, Fajas L, Held W, Dormond O, Romero P.

EBioMedicine. 2016 Jan 16;4:50-61. doi: 10.1016/j.ebiom.2016.01.019. eCollection 2016 Feb.

23.

NLRC5 shields T lymphocytes from NK-cell-mediated elimination under inflammatory conditions.

Ludigs K, Jandus C, Utzschneider DT, Staehli F, Bessoles S, Dang AT, Rota G, Castro W, Zehn D, Vivier E, Held W, Romero P, Guarda G.

Nat Commun. 2016 Feb 10;7:10554. doi: 10.1038/ncomms10554.

24.

Epitope located N-glycans impair the MHC-I epitope generation and presentation.

Chiritoiu GN, Jandus C, Munteanu CV, Ghenea S, Gannon PO, Romero P, Petrescu SM.

Electrophoresis. 2016 Jun;37(11):1448-60. doi: 10.1002/elps.201500449. Epub 2016 Feb 3.

PMID:
26701645
25.

High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools.

Chevalier MF, Bobisse S, Costa-Nunes C, Cesson V, Jichlinski P, Speiser DE, Harari A, Coukos G, Romero P, Nardelli-Haefliger D, Jandus C, Derré L.

Oncoimmunology. 2015 May 27;4(10):e1029702. eCollection 2015 Oct.

26.

Corrigendum: the antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis.

Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, Chamilos G, Feldmeyer L, Marinari B, Chon S, Vence L, Riccieri V, Guillaume P, Navarini AA, Romero P, Costanzo A, Piccolella E, Gilliet M, Frasca L.

Nat Commun. 2015 Mar 11;6:6595. doi: 10.1038/ncomms7595. No abstract available.

27.

CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis.

Trabanelli S, Curti A, Lecciso M, Salomé B, Riether C, Ochsenbein A, Romero P, Jandus C.

Haematologica. 2015 Jul;100(7):e257-60. doi: 10.3324/haematol.2014.119602. Epub 2015 Feb 20. No abstract available.

28.

The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis.

Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, Chamilos G, Feldmeyer L, Marinari B, Chon S, Vence L, Riccieri V, Guillaume P, Navarini AA, Romero P, Costanzo A, Piccolella E, Gilliet M, Frasca L.

Nat Commun. 2014 Dec 3;5:5621. doi: 10.1038/ncomms6621. Erratum in: Nat Commun. 2015;6:6595.

PMID:
25470744
29.

Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8(+) T cells with detection by ELISPOT and HLA-multimer staining.

Chudley L, McCann KJ, Coleman A, Cazaly AM, Bidmon N, Britten CM, van der Burg SH, Gouttefangeas C, Jandus C, Laske K, Maurer D, Romero P, Schröder H, Stynenbosch LF, Walter S, Welters MJ, Ottensmeier CH.

Cancer Immunol Immunother. 2014 Nov;63(11):1199-211. doi: 10.1007/s00262-014-1593-0. Epub 2014 Aug 19.

30.

Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.

Jandus C, Boligan KF, Chijioke O, Liu H, Dahlhaus M, Démoulins T, Schneider C, Wehrli M, Hunger RE, Baerlocher GM, Simon HU, Romero P, Münz C, von Gunten S.

J Clin Invest. 2014 Apr;124(4):1810-20. doi: 10.1172/JCI65899. Epub 2014 Feb 24.

31.

The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells.

Trabanelli S, Očadlíková D, Ciciarello M, Salvestrini V, Lecciso M, Jandus C, Metz R, Evangelisti C, Laury-Kleintop L, Romero P, Prendergast GC, Curti A, Lemoli RM.

J Immunol. 2014 Feb 1;192(3):1231-40. doi: 10.4049/jimmunol.1300720. Epub 2014 Jan 3.

32.

Alginate-coated chitosan nanogel capacity to modulate the effect of TLR ligands on blood dendritic cells.

Démoulins T, Bassi I, Thomann-Harwood L, Jandus C, Kaeuper P, Simon HU, von Gunten S, McCullough KC.

Nanomedicine. 2013 Aug;9(6):806-17. doi: 10.1016/j.nano.2013.01.002. Epub 2013 Jan 22.

PMID:
23347894
33.

Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma.

Bron L, Jandus C, Andrejevic-Blant S, Speiser DE, Monnier P, Romero P, Rivals JP.

Int J Cancer. 2013 Feb 1;132(3):E85-93. doi: 10.1002/ijc.27728. Epub 2012 Oct 3.

34.

Virus-like particles induce robust human T-helper cell responses.

Braun M, Jandus C, Maurer P, Hammann-Haenni A, Schwarz K, Bachmann MF, Speiser DE, Romero P.

Eur J Immunol. 2012 Feb;42(2):330-40. doi: 10.1002/eji.201142064. Epub 2011 Dec 2.

35.

Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells.

Baumgaertner P, Jandus C, Rivals JP, Derré L, Lövgren T, Baitsch L, Guillaume P, Luescher IF, Berthod G, Matter M, Rufer N, Michielin O, Speiser DE.

Int J Cancer. 2012 Jun 1;130(11):2607-17. doi: 10.1002/ijc.26297. Epub 2011 Aug 24.

36.

Targeting siglecs--a novel pharmacological strategy for immuno- and glycotherapy.

Jandus C, Simon HU, von Gunten S.

Biochem Pharmacol. 2011 Aug 15;82(4):323-32. doi: 10.1016/j.bcp.2011.05.018. Epub 2011 May 31. Review.

PMID:
21658374
37.

Quantitative multiparameter assays to measure the effect of adjuvants on human antigen-specific CD8 T-cell responses.

Derré L, Jandus C, Baumgaertner P, Posevitz V, Devêvre E, Romero P, Speiser DE.

Methods Mol Biol. 2010;626:231-49. doi: 10.1007/978-1-60761-585-9_16.

PMID:
20099132
38.

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.

Derré L, Rivals JP, Jandus C, Pastor S, Rimoldi D, Romero P, Michielin O, Olive D, Speiser DE.

J Clin Invest. 2010 Jan;120(1):157-67. doi: 10.1172/JCI40070. Epub 2009 Dec 28.

39.

Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.

Jandus C, Bioley G, Dojcinovic D, Derré L, Baitsch L, Wieckowski S, Rufer N, Kwok WW, Tiercy JM, Luescher IF, Speiser DE, Romero P.

Cancer Res. 2009 Oct 15;69(20):8085-93. doi: 10.1158/0008-5472.CAN-09-2226. Epub 2009 Oct 6.

40.

Recent advances and hurdles in melanoma immunotherapy.

Jandus C, Speiser D, Romero P.

Pigment Cell Melanoma Res. 2009 Dec;22(6):711-23. doi: 10.1111/j.1755-148X.2009.00634.x. Epub 2009 Sep 7. Review.

PMID:
19735459
41.

Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides.

Jandus C, Bioley G, Rivals JP, Dudler J, Speiser D, Romero P.

Arthritis Rheum. 2008 Aug;58(8):2307-17. doi: 10.1002/art.23655.

42.

Selective accumulation of differentiated FOXP3(+) CD4 (+) T cells in metastatic tumor lesions from melanoma patients compared to peripheral blood.

Jandus C, Bioley G, Speiser DE, Romero P.

Cancer Immunol Immunother. 2008 Dec;57(12):1795-805. doi: 10.1007/s00262-008-0507-4. Epub 2008 Apr 15.

PMID:
18414854
43.

Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma.

Appay V, Voelter V, Rufer N, Reynard S, Jandus C, Gasparini D, Lienard D, Speiser DE, Schneider P, Cerottini JC, Romero P, Leyvraz S.

J Immunother. 2007 Feb-Mar;30(2):240-50.

PMID:
17471171
44.

Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.

Bioley G, Jandus C, Tuyaerts S, Rimoldi D, Kwok WW, Speiser DE, Tiercy JM, Thielemans K, Cerottini JC, Romero P.

J Immunol. 2006 Nov 15;177(10):6769-79.

45.

New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.

Appay V, Jandus C, Voelter V, Reynard S, Coupland SE, Rimoldi D, Lienard D, Guillaume P, Krieg AM, Cerottini JC, Romero P, Leyvraz S, Rufer N, Speiser DE.

J Immunol. 2006 Aug 1;177(3):1670-8.

Supplemental Content

Loading ...
Support Center